The Acute Physiology and Chronic Health Evaluation (APACHE) III-j model has been used for benchmarking intensive care unit (ICU) outcomes in Australia and New Zealand for over a decade. This study assessed performance of the APACHE III-j model in adult patients admitted to Australasian ICUs during a ten-year period.
Prognostic models have been used for predicting patient outcomes in intensive care units (ICU) for over two decades 1 . The Acute Physiology and Chronic Health Evaluation (APACHE) [2] [3] [4] [5] , Simplified Acute Physiology Score [6] [7] [8] [9] and Mortality Probability Model [10] [11] [12] [13] are the main prognostic models. These scoring systems allow researchers to quantify overall patient illness severity with a greater degree of accuracy when evaluating practice patterns and outcomes in ICUs 14 .
APACHE is one of the most widely used scoring systems in critically ill adult patients. The original APACHE 2 (version 1) was developed in 1981 which provided an acute severity score using weightings for 34 physiological measurements. A simplified version, APACHE II 3 , was introduced in 1985 based on 5815 ICU admissions. This version used scores for 12 physiological variables, age, chronic health conditions and weightings for post-emergency surgery and disease categories to estimate the risk of hospital death. In 1991, the APACHE III prognostic system 4 , comprising of an APACHE III score and an APACHE III prediction equation, was developed on 17,440 admissions. By scoring the worst measurements of 17 physiological variables in the first 24 hours of ICU admission, along with age and chronic disease, an APACHE III score is calculated. A predicted risk of hospital death is then derived using this score in a logistic regression model by applying weights for various disease categories and treatment location prior to ICU admission. The APACHE IV 5 model is the most recent version available from 2006 but the required variables for this are not collected in Australia and New Zealand.
The Australian and New Zealand Intensive Care Society (ANZICS) 15 Centre for Outcomes and Resource Evaluation (CORE) has adopted APACHE methodology as the preferred model for benchmarking 16 . Most of the ICUs in Australia and New Zealand collect variables for APACHE models (II and III) and submit these data to ANZICS CORE for research and benchmarking purposes 17 . Data are collected under the Quality Assurance legislation of the Commonwealth of Australia (Part VC Health Insurance Act 1973, Commonwealth of Australia). Such data are collected with government support and funding. Data are submitted on behalf of each ICU director to the ANZICS Adult Patient Database (APD), one of three registries run by ANZICS CORE. Each hospital allows subsequent use as appropriate under the ANZICS CORE standing procedures and in compliance with the ANZICS CORE terms of reference. The ANZICS APD is one of the largest datasets in the world with over 1.2 million ICU admissions and has been well described previously 18 .
Following the release of APACHE III-j (tenth version of APACHE III) into the public domain in 2002 19 , it has been used for evaluating severity of illness for ICU patients in Australia and New Zealand and benchmarking ICU performance. It was hypothesised that this model would perform satisfactorily in Australasian ICUs for predicting patient outcomes. While performance of this model has been validated in individual institutions 17, 20 , this tool has not been evaluated for its predictive accuracy in a large cohort of ICU patients in Australia or New Zealand. The aim of this study was to assess performance of the APACHE III-j model by comparing observed hospital mortality with predicted mortality for adult patients admitted to Australasian ICUs during a ten-year period. More specifically, the authors sought to investigate performance of the model over time in various diagnostic categories and age strata.
MATERIAlS AND METHODS
Data pertaining to all ICU admissions between 1 January 2000 and 31 December 2009 were extracted from the ANZICS APD for this study. Patients below 16 years of age, re-admissions, ICU length-of-stay less than four hours, transfers to other ICUs and those with unknown hospital outcome or APACHE III predicted risk of death were excluded. Variables extracted included date of admission, age, APACHE III predicted risk of death, APACHE III diagnoses and hospital outcome. Access to the data was granted by the ANZICS CORE Management Committee in accordance with standing protocols. All data were deidentified and the study was conducted with approval Table 1 Measures of model performance
Hosmer-Lemeshow goodness-of-fit
Hosmer and lemeshow proposed two goodness-of-fit statistics for binary outcome data, C and H 24 , representing the chi-square test statistics for perfect calibration. Observations are grouped into ten groups based on either quantiles of predicted probability (C statistic) or equally spaced cut-points (H statistic), and the observed and expected outcomes are compared.
Brier's score, B
The Brier score, B 22 is an overall measure of the accuracy of predictions: Perfect prediction, B=0 Poor prediction, when a constant of 0.5 is assigned to every individual, B=0.25 B is the mean square error between outcomes and predictions.
SMR
The SMR is a ratio of observed mortality to the aggregate predicted mortality. Confidence intervals 21 are estimated around the observed mortality, using exact limits for the F distribution. Perfect prediction, SMR=1 Observed mortality higher than predicted, SMR >1
Cox calibration regression
The Cox calibration regression 23 provides a simple method to quantify the degree of miscalibration of a model. Cox suggested fitting the model True log odds=a+b×predicted log odds Using logistic regression: Perfect prediction, a=0 and b=1
AUROC
The AUROC 25 provides an indication of how well the model can discriminate between patients who die and patients who survive: Perfect discrimination, AUROC=1 Poor or no discrimination, AUROC=0.5
SMR=standardised mortality ratio, AUROC=area under the receiver operating characteristic curve. 
Statistical analysis
To assess the performance of APACHE III-j at different time points and within different age strata, admission type and hospital type, the whole cohort was divided into five 'two-year' groups. Markers of calibration and discrimination were investigated for each period. Calibration or goodness-of-fit refers to the ability of the model to assign correct probabilities of outcome to individual patients. In the absence of a single agreed method to measure overall goodnessof-fit, we used a combination of methods: Brier score, Hosmer-Lemeshow goodness-of-fit, standardised mortality ratio (SMR) and Cox calibration regression ( Table 1) [21] [22] [23] [24] . For visual inspection, calibration curves were drawn. Model discrimination refers to the ability of the model to assign higher probabilities of death to patients who actually die than to those patients who live. This was measured by area under the receiver operating characteristic curve 25 To quantify trends and changes within specific diagnoses and overall during the ten-year period, annual SMRs were used. The annual SMR for each diagnosis was calculated. Distribution of these SMRs were assessed for normality and found to be well approximated by a normal distribution after logarithmic transformation. We then performed linear regression analysis using log transformed SMRs as the outcome variable and time as the predictor variable. Time was entered as a continuous variable in the regression model. The results from linear regression analysis were reported as slope estimates with corresponding standard errors.
All analyses were performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA) and Stata version 11 (StataCorp, Texas, USA). Statistical significance was given by a two-sided P value of 0.05.
RESUlTS

Data analysed
There were 778,863 ICU admissions in Australia and New Zealand whose data were submitted to the ANZICS APD between 1 January 2000 and 31 December 2009. A total of 74,153 admissions were excluded from the analysis (12,252 below 16 years of age, 40,390 re-admission episodes, 12,653 ICU length-of-stay less than four hours excluded in accordance with APACHE III-j algorithm and 8858 transferred to other ICUs excluded in accordance with ANZICS CORE standard procedures). APACHE III-j predicted risk of death was not available for 133,573 admissions. Of these, 45,994 were patients who underwent coronary artery bypass surgery prior to routine introduction of the APACHE III-j algorithm for this diagnosis in September 2007 at all submitting sites. Prior to this date, at the majority of sites, patients with this diagnosis were not allocated a predicted risk of death. The introduction of this algorithm into routine practice directly accounts for the reduction in the number of admissions without an APACHE III-j risk of death seen in the final cohort (2008-2009). In 12,552 admissions there was no recorded hospital outcome. These exclusions left 558,585 admissions for analysis which represented 85% of all eligible admissions ( Figure 1 ). Table 2 shows descriptive information about the cohort who were predominantly male and had a mean age of around 60 years. Approximately 40% of patients were planned admissions following elective surgery and 20% had one or more chronic illness(es).
Descriptive findings
The observed mortality rate decreased every year 
Overall performance of APACHE III-j over time
The annual SMR for each year is shown in Figure 2 . There was a gradual reduction in SMR over the ten-year study period. The SMR was 1.02 (95% CI 0.99 to 1.05) in 2000 which reduced to 0.76 (0.75 to 0.78) in 2009. In the first three years (2000) (2001) (2002) , the SMR was around one (1.00 in 2001, 0.99 in 2002) and the corresponding 95% CI included one suggesting observed outcomes were not significantly worse than predicted outcomes. In contrast, from 2003 onwards the 95% CI of the SMR remained below one indicating that observed outcomes were significantly lower than predicted. Table 3 . APACHE III-j retained good discrimination during the study period with an area under the receiver operating characteristic curve of about 0.88. Despite this, there was progressive loss of calibration over a ten-year period. The Hosmer-lemeshow statistic steadily increased from 2000-2001 to 2008-2009 and SMRs gradually decreased, both suggesting increased lack-of-fit for the model over time. Figure 3A shows SMR for each ten-yearly age group. In the 2000-2001 cohort, the SMR was significantly different from 1 for only three of the eight age groups. Conversely, the SMR was well below 1 for all age groups in the 2008-2009 cohort, although it increased almost linearly with age. The calibration curve for APACHE III for different age cohorts is shown in Figure 3B .
Performance of APACHE III-j in subgroups
The calibration curves for 2000-2001 and 2008-2009 cohorts are shown in Figure 4 . While both curves showed loss of calibration, the deviation from perfect calibration was greater for the 2008-2009 cohort. Table 4A presents SMRs and slope estimates of annual change in SMR for the ten most prevalent diagnostic categories. The SMRs varied across diagnoses over time. While the SMR was above 1 in four diagnostic groups in 2000-2001, it was well below 1 for all in 2008-2009. Valvular heart surgery patients had the lowest SMR in each of the five cohorts examined.
Analysis of change in annual SMR showed that eight of ten most common diagnoses had a significant decrease in SMR over a ten-year period. The rate of decrease was not uniform across diagnostic groups. The greatest decrease was seen in patients who had 'coronary artery bypass grafts' (although data were not available for this diagnosis for the whole time period) followed by 'drug overdose', 'gastrointestinal neoplasm' and 'other gastrointestinal diseases'. SMRs over time according to admission type and major diagnostic group are presented in Tables 4B and 4C.  Table 4B shows that patients admitted as planned admissions to the ICU following elective surgery had the greatest decrease in SMR over time. Table 5 displays SMRs by hospital type. Although the SMRs decreased over time in all hospital types, the decrease was greater in rural and private hospitals. 
DISCUSSION
This paper reports performance of the APACHE III-j hospital mortality model in Australia and New Zealand during a ten-year period. It provides updated information about performance of the model currently used to monitor ICU performance in this region. It confirms that, despite good discrimination, the APACHE III-j model has lost its initially adequate calibration (Figure 2 ) in the Australasian adult ICU population. This loss of calibration is most likely the result of the continuing decline in mortality, but other factors are also likely to influence this.
The finding that the APACHE III-j model does not perform well in Australia is consistent with one other small regional study. Ten years ago Cook et al 20 found good performance for the APACHE III model in a single institution evaluation. More recently Duke et al 17 conducted a prospective study at a university affiliated metropolitan hospital and concluded that this model overpredicted mortality risk in their patient cohort. To the best of our knowledge, no study has been done in New Zealand to assess APACHE III performance.
Studies of the APACHE III model performance in other countries have been previously published, which suggests poor calibration for the model in countries other than the USA where it was originally developed. Harrison et al 26 assessed APACHE III performance on 231,930 admissions and found that model calibration was poor in the UK cohort. Independent evaluations carried out in Germany 27 and Brazil 28 also yielded similar results.
Perfect performance of a mortality prediction model in different countries during different time periods supposes that all relevant factors which affect the outcome are included and remain in the same 30 and data quality 19, 20 are known to disrupt goodness-of-fit models. In our study, the observed mortality rate was noted to decline from 17% in 2000 to 10.6% in 2009. While this was accompanied by a reduction in predicted mortality, the decline in observed mortality was greater. Although it is reassuring for clinicians to see outcomes appearing to improve progressively, it may well be that this was due to a change in the distribution of factors affecting outcomes and this accounted for the changing performance of APACHE III-j. The most significant of these is variation in case-mix, as explained below.
Different model performance within subgroups means that variation in the proportion of each subgroup, making up the whole cohort, will affect overall calibration of the model. later years saw the introduction of a large number of patients with coronary artery bypass graft surgery in whom observed deaths were lower than predicted and who contributed to the overall reduction in SMR and model performance. A reduction in SMR was seen for most of the top diagnoses but it was greater for some groups ( 2000-2009 (continued) its performance for each diagnosis was not consistent over time. This suggests that not only does case-mix variation contribute to the overall performance of APACHE III-j, but the impact of this variation is greater in later years than in the early 2000s.
The mean age of patients increased from 58.9 years in 2000 to 61.2 years in 2009. APACHE III retained relatively better calibration in the more elderly age groups over time. In addition, the calibration in the elderly is best at low levels of predicted risk which represents the largest volume of these patients. The increasing numbers of patients over time is thus not likely to be as important a factor influencing the loss of calibration compared to other factors such as changing case-mix and improvements in overall mortality outcomes.
Changes in data quality can also affect model performance. Any improvement in data quality can result in more accurate mortality prediction which in turn can disrupt the model fit. In the present study, the data quality may have improved with time ( Table  2) . Nearly 5% of all submissions to the APD had no recorded outcome in the first two years. This was about 1% in later years. The APD has a number of features that are required to maintain a high quality database 18 . Data received at ANZICS CORE from contributing ICUs are processed through a number of error-checking procedures and a data quality report is returned to each ICU for correction. Furthermore, ANZICS CORE have introduced on-site audits to monitor data quality, but it is not known if specific data collection methods have changed over the ten years examined. The impact of these factors on data quality and their subsequent effect on model performance was not assessed in this paper.
Our study has some strengths. This is the first study to assess APACHE III-j model performance in a large cohort of ICU patients in Australia and New Zealand. ANZICS APD is one of the largest ICU databases in the world with over one million ICU admissions. The magnitude of this database enabled us to assess model performance over time and also in specific patient subgroups such as age and diagnosis. The present study has assessed calibration using a variety of methods. Although the Hosmer-lemeshow method is the most commonly used measure of calibration, it has limited applicability when used with large datasets 31 . We therefore used four additional methods. Regardless of the type of method used, each measure showed lack-of-fit for the current APACHE III-j model. limitations of the current analysis also require mention. Although the data were extensively checked and cleaned by ANZICS, a considerable proportion of eligible admissions (15.2%) could not be included due to poor data quality with no recorded hospital outcomes or no APACHE III-j predicted risk of death ( Figure 1 ). While the demographics of this missing cohort were similar to our population of interest, their impact on model performance cannot be determined. Furthermore, generalisability could be an issue. A model developed in another country and applied to Australasia should be rigorously validated. If the model used does not fit the data to which it is applied, conclusions drawn from its use may be wrong. Our results may not be applicable to ICUs outside Australia and New Zealand. Despite the limitations, our study demonstrates that the current APACHE III-j model has lost its calibration in the Australian and New Zealand ICU population and may no longer be adequate for monitoring performance. Better mortality prediction will require the development of a new model specifically tailored to this population.
CONClUSION
This study confirms that performance of the APACHE III-j model has deteriorated in Australasian hospitals. The model now has poor calibration over age strata, type of admission, hospital type and within the most prevalent diagnostic categories. There is now a need to develop an updated model specifically tailored to this population to improve mortality prediction and quality of research undertaken in the Australasian ICU population. While this updated modelling could primarily be achieved through recalibration of regression coefficients, there is also scope for the addition of new variables that were not included in the original APACHE equations. Further research is needed to identify and quantify the factors that may account for the decrease in SMR over time.
